{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:57:00Z","timestamp":1792177020683,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010369","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000}}],"reference-count":119,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010369.pub2","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T14:02:36Z","timestamp":1484316156000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews"],"prefix":"10.1002","volume":"2017","author":[{"given":"Anne Louise","family":"Oaklander","sequence":"first","affiliation":[{"name":"Mass General Hospital; 275 Charles St.\/Warren 310 Boston Massachusetts USA MA 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael PT","family":"Lunn","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; Department of Neurology and MRC Centre for Neuromuscular Diseases; Queen Square London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard AC","family":"Hughes","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; PO Box 114 Queen Square London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Academic Medical Centre, University of Amsterdam; Department of Neurology; Meibergdreef 9 PO Box 22700 Amsterdam Netherlands 1100 DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Frost","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Department of Medical Statistics; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin H","family":"Chalk","sequence":"additional","affiliation":[{"name":"McGill University; Department of Neurology & Neurosurgery; Montreal General Hospital - Room L7-313 1650 Cedar Avenue Montreal QC Canada H3G 1A4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"10.1002\/14651858.CD010369.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"CD001797","DOI":"10.1002\/14651858.CD001797.pub3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Eftimov","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0002|cit2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002062.pub3","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Hughes","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0003|cit3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003280.pub3","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mahdi-Rogers","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0004|cit4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003906.pub4","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0005|cit5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005376.pub3","article-title":"Treatment for IgG and IgA paraproteinaemic neuropathy","author":"Stork","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2377-14-26","article-title":"Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review","volume":"14","author":"Bright","year":"2013","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"96-104","DOI":"10.1016\/j.ejphar.2014.11.033","article-title":"Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials","volume":"747","author":"Buehler","year":"2015","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD010369.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","article-title":"Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions: report of the AANEM ad hoc committee","volume":"40","author":"Donofrio","year":"2009","journal-title":"Muscle & Nerve"},{"issue":"9","key":"10.1002\/14651858.CD010369.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"European Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD010369.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/j.1537-2995.2005.00581.x","article-title":"Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review","volume":"45","author":"Fergusson","year":"2005","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0012|cit12","first-page":"e154-e166","article-title":"Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"4","author":"Gaebel","year":"2010","journal-title":"Open Medicine"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-444-52902-2.00023-0","article-title":"Treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"115","author":"Lehmann","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"issue":"13","key":"10.1002\/14651858.CD010369.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous vs. intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","author":"Racosta","journal-title":"Muscle & Nerve"},{"issue":"1-2","key":"10.1002\/14651858.CD010369.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.01.003","article-title":"A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"326","author":"St\u00fcbgen","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision","volume":"17","author":"Bergh","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/B978-0-444-52910-7.00037-4","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"112","author":"Vanasse","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.23821","article-title":"Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity?","volume":"48","author":"Ayrignac","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/01.STR.20.6.828","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"20","author":"Bamford","year":"1989","journal-title":"Stroke"},{"issue":"7","key":"10.1002\/14651858.CD010369.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40261-016-0401-3","article-title":"Economic evaluation of intravenous immunoglobulin plus corticosteroids for the treatment of steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy in Thailand","volume":"36","author":"Bamrungsawad","year":"2016","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0022|cit22","unstructured":"Becker LA Oxman AD Chapter 22: Overview of reviews Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-7547-8-14","article-title":"Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada","volume":"8","author":"Blackhouse","year":"2010","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mus.21733","article-title":"Electrophysiologic correlations with clinical outcomes in CIDP","volume":"42","author":"Bril","year":"2010","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.20075","article-title":"Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data","volume":"30","author":"Bromberg","year":"2004","journal-title":"Muscle & Nerve"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD010369.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"P7.092","DOI":"10.1212\/WNL.82.10_supplement.P7.092","article-title":"Multicentre, randomised, open-label trial to compare efficacy and tolerance of prednisone and IVIg in patients with CIDP on a one year follow up","volume":"82","author":"Camdessanch\u00e9","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Cocito","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0028|cit28","first-page":"1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study","volume":"46","author":"Confavreux","year":"1996","journal-title":"Clinical & Vaccine Immunology: CVI"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0029|cit29","first-page":"258","article-title":"The point trial: answering important unaddressed issues in the treatment of CIDP with IVIg","volume":"15","author":"Cornblath","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jca.2920090102","article-title":"Complications of therapeutic plasma exchange: a recent assessment","volume":"9","author":"Couriel","year":"1994","journal-title":"Journal of Clinical Apheresis"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00415-011-6200-0","article-title":"Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design","volume":"259","author":"Deng","year":"2012","journal-title":"Journal of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010369.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","article-title":"Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin","volume":"57","author":"Donaghy","year":"1994","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010369.pub2-BIB0034|cit34","first-page":"79","article-title":"Side-effects of intravenous immune globulins","volume":"97","author":"Duhem","year":"1994","journal-title":"Clinical and Experimental Immunology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","article-title":"Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD010369.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/B978-0-7216-9491-7.50043-0","article-title":"Quantitating overall neuropathic symptoms, impairments, and outcomes","volume-title":"Peripheral Neuropathy","author":"Dyck","year":"2005"},{"issue":"14","key":"10.1002\/14651858.CD010369.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.0b013e31824e8f84","article-title":"Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment","volume":"78","author":"Eftimov","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jns.12129","article-title":"Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, randomized controlled non-inferiority trial (IOC trial)","volume":"20","author":"Eftimov","year":"2015","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010369.pub2-BIB0043|cit43","first-page":"S48","article-title":"Oral fingolimod (FTY720) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): study design of the phase 3 FORCIDP trial","volume":"18","author":"Hughes","year":"2013","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0044|cit44","unstructured":"Gaebel K Blackhouse G Campbell K Robertson D Xie F Assasi N Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy: Clinical- and cost-effectiveness analyses. Technology report number 117 Ottawa: Canadian Agency for Drugs and Technologies in Health 2009"},{"issue":"9665","key":"10.1002\/14651858.CD010369.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0046|cit46","unstructured":"Brozek J, Oxman A, Sch\u00fcnemann H GRADEpro 2008"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale","volume":"77","author":"Graham","year":"2006","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"7650","key":"10.1002\/14651858.CD010369.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.53.1.57","article-title":"Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"53","author":"Hadden","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119 (Pt 4)","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119 (Pt 4)","author":"Hahn","year":"1996","journal-title":"Brain"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010369.pub2-BIB0052|cit52","first-page":"41","article-title":"A randomised, double-blinded, placebo-controlled trial of the effect of subcutaneous immunoglobulin on muscular performance in chronic inflammatory de-myelinating polyneuropathy","volume":"259","author":"Harbo","year":"2012","journal-title":"Journal of Neurology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD010369.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"P6.103","DOI":"10.1212\/WNL.82.10_supplement.P6.103","article-title":"Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial","volume":"82","author":"Hartung","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010369.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1371\/journal.pmed.0020164","article-title":"Analgesic therapy in postherpetic neuralgia: a quantitative systematic review","volume":"2","author":"Hempenstall","year":"2005","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0055|cit55","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD010369.pub2-BIB0056|cit56","first-page":"649","article-title":"[Clinical observation on treatment of 10 patients with chronic inflammatory demyelinating polyneuropathy by gullong tongluo capsule combined with prednisone]","volume":"29","author":"Hu","year":"2009","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"8093","key":"10.1002\/14651858.CD010369.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial of prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/ern.09.30","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial","volume":"9","author":"Hughes","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jocn.2012.10.026","article-title":"Significant dermatological side effects of intravenous immunoglobulin","volume":"20","author":"Hurelbrink","year":"2013","journal-title":"Journal of Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0317167100014359","article-title":"Home IVIG for CIDP: a focus on patient centred care","volume":"40","author":"Katzberg","year":"2013","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-beta in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jca.1024","article-title":"Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures","volume":"16","author":"Kiprov","year":"2001","journal-title":"Journal of Clinical Apheresis"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.36.1.35","article-title":"Azathioprine toxicity in neuromuscular disease","volume":"36","author":"Kissel","year":"1986","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD010369.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle & Nerve"},{"issue":"12","key":"10.1002\/14651858.CD010369.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/jnnp.2010.206599","article-title":"Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"81","author":"Kuitwaard","year":"2010","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0070|cit70","unstructured":"Kuitwaard K Vrancken A Brusse E Eftimov F Notermans N Van der Kooi A Dose response trial of IV immunoglobulin in CIDP (drip study) Inflammatory Neuropathy Consortium of the Peripheral Nerve Society Meeting Programme 2016 86"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0071|cit71","first-page":"268","article-title":"A phase III trial of gammagard liquid (Kiovig) in CIDP","volume":"15","author":"Lee","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD010369.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mus.24942","article-title":"Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease","volume":"53","author":"Lozeron","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"10","key":"10.1002\/14651858.CD010369.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002827.pub3","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","author":"Lunn","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Pt 1","key":"10.1002\/14651858.CD010369.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"L\u00e9ger","year":"2001","journal-title":"Brain"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0075|cit75","volume-title":"The Epidemiology and Treatment of Chronic Acquired Neuropathies [MD Thesis]","author":"Mahdi-Rogers","year":"2010"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0076|cit76","first-page":"259","article-title":"A randomized, double-blind, placebo-controlled trial of the effect of subcutaneous immunoglobulin on muscular performance in chronic inflammatory demyelinating polyneuropathy","volume":"17","author":"Markvardsen","year":"2012","journal-title":"Journal of the Peripheral Nervous System : JPNS"},{"issue":"5","key":"10.1002\/14651858.CD010369.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010369.pub2-BIB0078|cit78","first-page":"909","article-title":"Subcutaneous versus intravenous immunoglobulin in drug-na\u00efve patients with chronic inflammatory demyelinating polyneuropathy (CIDP)-a randomised, single-blind, cross-over trial","volume":"23","author":"Markvardsen","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0079|cit79","first-page":"181","article-title":"Safety and tolerability of intravenous immunoglobulins","volume-title":"Treatment of Neurological Disorders with Intravenous Immunoglobulins","author":"Martin","year":"2000"},{"issue":"9","key":"10.1002\/14651858.CD010369.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"McCrone","year":"2003","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2012.09.008","article-title":"Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series","volume":"23","author":"McMillan","year":"2013","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD010369.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":"Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies","volume":"72","author":"Merkies","year":"2002","journal-title":"Journal of Neurology Neurosurgery & Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD010369.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1529-8027.2010.00274.x","article-title":"Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study","volume":"15","author":"Merkies","year":"2010","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0090|cit90","unstructured":"NCT00962429 Lipoic acid to treat chronic inflammatory demyelinating polyneuropathy clinicaltrials.gov\/show\/NCT00962429"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0091|cit91","unstructured":"NCT01545076 Chronic inflammatory demyelinating polyneuropathy (CIDP) and treatment with subcutaneous immunoglobulin (IgPro20) clinicaltrials.gov\/show\/NCT01545076"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0092|cit92","unstructured":"NCT01625182 Evaluate efficacy and safety of fingolimod 0.5 mg orally once daily versus placebo in chronic inflammatory demyelinating polyradiculoneuropathy patients http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01625182"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010369.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0096|cit96","unstructured":"Pouget J Desnuelle C Antoine J-C Lacour A De Seze J Vial C A comparative, double-blind, randomized, multicentre clinical trial to access the efficacy and safety of clairyg vs. tegeline in maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Inflammatory Neuropathy Consortium of the Peripheral Nerve Society Meeting Programme; 2016 June 21-24; Glasgow http:\/\/www.inc2016glasgow.co.uk\/assets\/programme-v17-_-delegates.pdf 2016 79"},{"issue":"10","key":"10.1002\/14651858.CD010369.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD010369.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/jnnp-2013-306105","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal","volume":"85","author":"Rabin","year":"2014","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010369.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4065\/70.6.532","article-title":"Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine","volume":"70","author":"Russell","year":"1995","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005454.pub2","article-title":"Antidepressants for neuropathic pain","author":"Saarto","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0103|cit103","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Medical Research Methodology"},{"issue":"10","key":"10.1002\/14651858.CD010369.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","article-title":"AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews","volume":"62","author":"Shea","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0106|cit106","first-page":"193-203","article-title":"Immunoglobulin therapy in primary antibody deficiency and HIV infection","volume-title":"Intravenous immunoglobulin: research and therapy. 1","author":"Stiehm","year":"1996"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","article-title":"A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"243","author":"Thompson","year":"1996","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","article-title":"High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. [see comment]","volume":"40","author":"Doorn","year":"1990","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"Schaik","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0111|cit111","unstructured":"Van Schaik IN Bril V Van Geloven N Hartung H-P Lewis RA Sobue G Randomized, double-blind placebo-controlled study to investigate the efficacy, safety and tolerability of two different doses of IGPRO20 (subcutaneous immunoglobulin) for the treatment of CIDP: IGG dependency and restabilization phase Inflammatory Neuropathy Consortium of the Peripheral Nerve Society Meeting Programme 2016 76 7"},{"key":"10.1002\/14651858.CD010369.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/B978-0-444-52910-7.00037-4","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"112","author":"Vanasse","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010369.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010369.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003904.pub2","article-title":"Exercise for people with peripheral neuropathy","author":"White","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"The Stata Journal"},{"issue":"12","key":"10.1002\/14651858.CD010369.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008146.pub2","article-title":"Interventions for fatigue in peripheral neuropathy","author":"White","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010369.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.transci.2005.07.010","article-title":"A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy","volume":"33","author":"Zinman","year":"2005","journal-title":"Transfusion and Apheresis Science"},{"issue":"2","key":"10.1002\/14651858.CD010369.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010369","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","author":"Hughes","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010369.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:35:53Z","timestamp":1749890153000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010369.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010369.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}